XML 29 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]              
Net revenue $ 12,582 $ 7,926 $ 23,164 $ 14,738 $ 38,034 $ 31,317 $ 23,560
Operating costs and expenses:              
Cost of revenue 4,177 1,529 7,768 2,673 10,797 3,634 2,149
Research and development 3,204 2,589 5,940 5,220 9,054 9,201 9,961
Selling, general and administrative 26,989 14,344 55,690 25,252 64,895 50,582 42,970
Intangible amortization 1,026 935 2,053 1,870 3,922 3,738 3,738
Total operating costs and expenses 35,396 19,397 71,451 35,015 88,668 67,155 58,818
Loss from operations (22,814) (11,471) (48,287) (20,277) (50,634) (35,838) (35,258)
Other (income) expense:              
Loss (gain) on derivative liability 82 2,700 5,335 (4,800) (8,310) 300 (800)
Loss on debt extinguishment, net 0 0 0 4,799 (28,634) 12,463 0
Scilex Pharma Notes principal increase         0 28,000 0
Change in fair value of Convertible debentures 3,748 0 3,748 0      
Interest expense         9,604 11,764 13,116
Interest expense, net 5 3,707 4 6,738      
Loss on foreign currency exchange 3 (12) 23 (8) 66 54 (2)
Total other expense 3,838 6,395 9,110 6,729 (27,274) 52,581 12,314
Loss before income taxes (26,652) (17,866) (57,397) (27,006) (23,360) (88,419) (47,572)
Income tax expense (3) (28) 5 (25) 4 5 (53)
Net loss $ (26,649) $ (17,838) $ (57,402) $ (26,981) $ (23,364) $ (88,424) $ (47,519)
Earnings Per Share [Abstract]              
Net loss per share attributable to common stockholders - basic $ (0.19) $ (0.13) $ (0.4) $ (0.2) $ (0.17) $ (0.67) $ (0.36)
Net loss per share attributable to common stockholders - diluted $ (0.19) $ (0.13) $ (0.4) $ (0.2) $ (0.17) $ (0.67) $ (0.36)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]              
Weighted average number of shares during the period-basic 142,626,000 133,060,000 142,146,000 133,043,000 134,226,000 132,858,000 132,891,000
Weighted average number of shares during the period -diluted 142,626,000 133,060,000 142,146,000 133,043,000 134,226,000 132,858,000 132,891,000